Partow Kebriaei, MD, from MD Anderson Cancer Center, discusses how nurses can monitor patients for cytokine release syndrome.
Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses what to be aware of when treating patients who have undergone CAR T-cell therapies.
Cytokine release syndrome (CRS) and other neurotoxicities often occur within the first 2 weeks after infusion of CAR T-cell therapy. During this time, symptoms such as fever may not seem alarming but can be indications of CRS. It is important to carefully monitor these patients through vitals, daily weight, and mental status. Close observation during the first weeks after the CAR T-cell therapy is necessary to catch CRS in these patients.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.